Pulse Biosciences Stock Alpha and Beta Analysis
| PLSE Stock | USD 16.99 0.14 0.82% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pulse Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pulse Biosciences over a specified time horizon. Remember, high Pulse Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pulse Biosciences' market risk premium analysis include:
Beta 0.93 | Alpha (0.01) | Risk 4.44 | Sharpe Ratio 0.0102 | Expected Return 0.0451 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Pulse |
Pulse Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pulse Biosciences market risk premium is the additional return an investor will receive from holding Pulse Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pulse Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pulse Biosciences' performance over market.| α | -0.0061 | β | 0.93 |
Pulse Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Pulse Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Pulse Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Pulse Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Pulse Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pulse Biosciences shares will generate the highest return on investment. By understating and applying Pulse Biosciences stock market price indicators, traders can identify Pulse Biosciences position entry and exit signals to maximize returns.
Pulse Biosciences Return and Market Media
The median price of Pulse Biosciences for the period between Fri, Dec 13, 2024 and Thu, Mar 13, 2025 is 18.66 with a coefficient of variation of 8.84. The daily time series for the period is distributed with a sample standard deviation of 1.68, arithmetic mean of 18.98, and mean deviation of 1.32. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Robert Duggan of 55256 shares of Pulse Biosciences at 17.18 subject to Rule 16b-3 | 12/13/2024 |
2 | Disposition of 24656 shares by Robert Duggan of Pulse Biosciences at 11.0 subject to Rule 16b-3 | 12/18/2024 |
3 | Acquisition by Paul LaViolette of 450000 shares of Pulse Biosciences at 18.43 subject to Rule 16b-3 | 01/08/2025 |
4 | Pulse Biosciences Nanosecond PFA Technology to be Featured in Multiple Presentations at the AF Symposium | 01/13/2025 |
5 | Pulse Biosciences Inc Unveils Promising Data from Cardiac Catheter Study | 01/21/2025 |
6 | Acquisition by Zanganeh Mahkam of 30121 shares of Pulse Biosciences at 11.0 subject to Rule 16b-3 | 01/24/2025 |
7 | Griffin Asset Management Inc. Has 4.14 Million Stake in Pulse Biosciences, Inc. - MarketBeat | 01/28/2025 |
8 | Pulse Biosciences Nanosecond PFA Technology to Be Featured in Presentations at North American Society for Interventional Thyroidology Annual Meeting | 01/30/2025 |
9 | Disposition of 30121 shares by Zanganeh Mahkam of Pulse Biosciences at 11.0 subject to Rule 16b-3 | 02/03/2025 |
10 | Pulse Biosciences appoints Jon Skinner as CFO | 02/04/2025 |
11 | Acquisition by Van Den Broek Richard of 20000 shares of Pulse Biosciences at 14.55 subject to Rule 16b-3 | 02/11/2025 |
12 | Pulse Biosciences Shares Down 7.8 percent - Heres Why - MarketBeat | 02/20/2025 |
13 | Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 03/04/2025 |
14 | Pulse Biosciences Schedules Fourth Quarter Full Year 2024 Financial Results Conference Call for March 27, 2025 | 03/07/2025 |
About Pulse Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pulse or other stocks. Alpha measures the amount that position in Pulse Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Payables Turnover | 0.59 | 0.56 | Days Of Inventory On Hand | 972.15 | 864.13 |
Pulse Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Pulse Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pulse Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pulse Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pulse Biosciences. Please utilize our Beneish M Score to check the likelihood of Pulse Biosciences' management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Pulse Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Pulse Biosciences Backtesting, Pulse Biosciences Valuation, Pulse Biosciences Correlation, Pulse Biosciences Hype Analysis, Pulse Biosciences Volatility, Pulse Biosciences History and analyze Pulse Biosciences Performance. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Pulse Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.